Navigation Links
Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Date:8/27/2007

EDISON, N.J., Aug. 27 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") and Ipca Laboratories Ltd. ("Ipca") announced today that they have entered in to a strategic alliance for the development, supply and marketing of generic pharmaceutical products for the U.S. prescription drug market. Under the Agreement, Ipca shall develop and register selected products for U.S. ANDA submission and Heritage retains sales and marketing rights to such products. The parties shall share net profits from the sales proceeds post-launch.

Commenting on the Agreement, Heritage President & CEO, Jeffrey Glazer, stated, "Our agreement with Ipca represents yet another important strategic partnership with an emerging, low cost developer and supplier of active ingredients and finished goods. These types of agreements enable Heritage to leverage our business model of strategic outsourcing to obtain a "virtually vertical" supply chain of quality generic products as we continue to expand our product offerings."

Heritage Pharmaceuticals Inc. is an emerging generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Heritage launched its U.S. label in 2006 and currently markets 3 products over 10 SKU's. The Company will continue to introduce its acquired multi-source generic product line during 2007-08 following its tradition of premier quality, value and service in generics.

Ipca Laboratories Ltd. is a fast growing fully integrated pharmaceutical company based in Mumbai, India engaged in the manufacturing and marketing of a range of pharmaceuticals with a thrust on international business. Ipca exports its Active Pharmaceutical Ingredients and Finished Dosages to over 110 countries across the globe, which contributed about 53% of the Company's total global income of $227mm in the financial year 2006-07. It has a strong focus on international business in the developed markets like Europe and North America.


'/>"/>
SOURCE Heritage Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NanoRite Innovation Center opens with small science, big promise
2. UW-Madison to receive $125M for bioenergy research center
3. WARF enters licensing agreements for stem cell products
4. Internet-enabled niche markets take center stage
5. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
6. TomoTherapy opens technical training center
7. Stem cell and regenerative medicine center to aid education and commerce
8. Mega-Metro Center may go beyond Chicago and Wisconsin
9. Software company enters health space with RFID solutions on hold
10. Former Fiserv exec to enter Business Hall of Fame
11. Berbee to expand at New Venture Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 22, 2017 , ... Researchers face a fundamental challenge as ... full-size tissues, bones, even whole organs to implant in people to treat disease ... into the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
(Date:3/22/2017)... 22, 2017 The global chronic ... research report by Transparency Market Research (TMR). The top ... and AbbVie Inc., accounted for a share of only ... in this market are focusing aggressively on mergers, acquisitions, ... is likely to lead to market consolidation in the ...
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
Breaking Biology Technology:
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
Breaking Biology News(10 mins):